The application of macrolids in the treatment of purulent nonrocrical complications of the diabetic stop syndrome

Here are the results of a prospective comparative randomized clinical, microbiological and cytological smears-imprint of the wounds of 65 patients with a neuropathic and neuroischemic (without critical ischemia) form of the diabetic foot syndrome complicated by the development of purulent necrotic process, prior to the treatment, on the 4th, 7th, 14th, 14th and on the 21st day of the treatment. The aim of the work is to increase the effectiveness of the therapy to the patients with purulent-necrotic complications of VDS by including a complex antibacterial therapy with a group of macrolides in the scheme. Two groups of patients were examined: 1st group - after the surgical treatment of wounds and intravenous introduction of antibacterial drugs selected according to antibioticogram results; 2 nd - after the surgical treatment of wounds and antibacterial therapy combined (drug, selected according to antibioticogram + clarithromycin).Based on the results of the cytological analysis of smears-prints and the dynamics of bacteriological landscape of the wound surface, the effectiveness of the complex antibacterial therapy with the inclusion of a group of macrolides is shown.At the same time, there was a reduction in both the inflammatory and reparative phases of the wound process, which made it possible to resort to plastic closure of wound defects at an earlier time. There were no complications in performing dermatomic autodermoplasty in the patients of the main group.

сахарный диабет, синдром диабетической стопы, кларитромицин, гнойно-некротические раны, антибактериальная терапия, diabetes mellitus, diabetic foot syndrome, clarithromycin, purulent-necrotic wounds, antibacterial therapy

1. International Diabetes Federation. IDF Diabetes Atlas. Sixth edition ed.; 2013.

2. Boulton A.J., Vileikyte L., Ragnarson-Tennval G., Apelgvist J. The global burden of diabetic foot disease. Lancet. 2005 Nov 12;366(9498):1719-1724.

3. Bus S.A., Van Netten J.J., Lavery L.A., Monteiro-Soares M., Rasmusen A., Jubiz Y., et al. IWGDF Guidance on the prevention of foot ulcers in at-risk patient with diabetes. Diabetes Metab Res Rev. 2016 Jan; 32 Supll 1:16-24.

4. Bus S.A., Armstrong D.G., Van Deursen R.W., Lewis J., Caravaggi C.F., Cavanagh P.R. IWGDF Guidance on Footwear and offloading interventions to prevent and heal foot ulcers in patient with diabetes. Diabetes Metab Res Rev. 2016 Jan; 32 Supll 1:99-118.

5. Абдуллоев Д.А., Набиев М.Х., Билолов М.К., Бега-ков У.М. Предотвращение ампутации у больных с осложненными формами синдрома диабетической стопы. 2015;(4):50-55.

6. Lipsky BA, Peters EJ Berendt AR, Senneville E, Bakker K, Embil JM, Lavery LA, Urbancic-Rovan V, Jeffcoate WJ, International Working Group on Diabetic Foot: Specific guidelines for the treatment of diabetic foot infections 2011. Diabetes Metab Res Rev 28 Suppl 1:234-235, 2012.

7. Пальцин А.А., Колокольчикова Е.Г., Земляной А.Б. Возбудители хирургической инфекции при поражениях нижних конечностей у больных сахарным диабетом. Анналы хирургии 2001;(5):50-6.

8. Peters EJ, Lipsky BA, Aragon-Sanchez J, Bakker K, Boyko EJ, Diggle M, Embil JM, Kono S, Lavery V LA, Senneville E, Urbancic-Rovan V, VanAsten SA, Jeffcoate WJ: A systematic review of interventions in the management of infection in the diabetic foot. Diabetes Metab Res Rev In Press: 2015.

9. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E: 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. Clin Infect Dis 54:e132-e173, 2012.